Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SpineGuard S.A. (ALSGD.PA)
Vincennes, FR
SpineGuard S.A. specializes in the global design, development, and commercialization of advanced medical instruments for surgical procedures. Their product line includes various PediGuard probes: the Straight probe for precise screw placement; the Curved probe, featuring a tapered tip to facilitate easier pedicle penetration; and the Cannulated probe, engineered to help surgeons minimize radiation exposure during minimally-invasive operations. They also offer the PediGuard Threaded Device, a specialized drilling tool. Complementing these devices, SpineGuard provides the DSG (Dynamic Surgical Guidance) Connect app, which collects and visualizes real-time signals from DSG-enabled instruments during pedicle drilling, alongside the DSG smart screw for streamlined one-step screw insertion. SpineGuard's innovative solutions serve a broad spectrum of healthcare stakeholders, including patients, surgeons, operating room staff, and other healthcare providers. Founded in 2009, the company is headquartered in Vincennes, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.83% | -1.04% | -1.96% | -22.76% | -30.66% | -5.94% | -12.52% | -84.72% | -93.87% | -98.05% | -98.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-19.2% Q4'25: -21.3% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+64.3% ★ Q4'25: +79.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-47.8% Q4'25: -28.4% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-44.2% Q4'25: -74.6% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-31.9% Q4'25: -93.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+87.7% Q4'25: +121.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.88× Q4'25: -0.30× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.62M
est: 4.77M (-3.3%)
|
4.36M
est: 4.77M (-8.6%)
|
6.23M
est: 6.35M (-1.9%)
|
7.46M
est: 7.46M (0.0%)
|
8.17M
est: 8.17M (0.0%)
|
7.58M
est: 7.58M (+0.0%)
|
6.83M
est: 6.80M (+0.4%)
|
4.85M
est: 4.85M (+0.0%)
|
4.41M
est: 4.41M (+0.0%)
|
5.60M
est: 5.60M (0.0%)
|
4.31M
est: 4.31M (0.0%)
|
4.65M
est: 4.65M (+0.0%)
|
3.76M
est: 3.76M (0.0%)
|
4.63M
4.63M – 4.63M
+23.2% YoY
|
5.67M
5.67M – 5.67M
+22.5% YoY
|
| EBITDA |
-3.04M
est: -2.04M (-48.8%)
|
-4.21M
est: -3.40M (-23.9%)
|
-3.63M
est: -5.58M (+35.0%)
|
-3.44M
est: -3.20M (-7.7%)
|
-3.16M
est: -3.50M (+9.7%)
|
-959.4K
est: -3.24M (+70.4%)
|
61.1K
est: -2.91M (+102.1%)
|
-1.59M
est: -2.08M (+23.2%)
|
-812.5K
est: -1.89M (+56.9%)
|
-1.27M
est: -2.40M (+47.2%)
|
-3.50M
est: -2.88M (-21.4%)
|
-2.75M
est: -2.10M (-31.1%)
|
-1.66M
est: -1.69M (+2.0%)
|
-2.09M
-2.09M – -2.09M
-23.2% YoY
|
-2.56M
-2.56M – -2.56M
-22.5% YoY
|
| EBIT |
-3.15M
est: -2.36M (-33.8%)
|
-4.23M
est: -3.15M (-34.4%)
|
-3.66M
est: -5.72M (+36.0%)
|
-3.52M
est: -3.69M (+4.6%)
|
-3.30M
est: -4.04M (+18.2%)
|
-1.24M
est: -3.74M (+66.9%)
|
-234.5K
est: -3.36M (+93.0%)
|
-1.95M
est: -2.40M (+18.8%)
|
-1.12M
est: -2.18M (+48.5%)
|
-1.56M
est: -2.77M (+43.7%)
|
-3.79M
est: -873.5K (-333.7%)
|
-3.06M
est: -2.33M (-31.1%)
|
-1.66M
est: -1.89M (+12.0%)
|
-2.33M
-2.33M – -2.33M
-23.2% YoY
|
-2.85M
-2.85M – -2.85M
-22.5% YoY
|
| Net Income |
-3.51M
est: -33.75M (+89.6%)
|
-4.54M
est: -3.51M (-29.3%)
|
-3.88M
est: -5.79M (+33.1%)
|
-4.18M
est: -29.30M (+85.7%)
|
-4.13M
est: -10.50M (+60.7%)
|
-2.33M
est: -7.87M (+70.4%)
|
-685.7K
est: -4.81M (+85.7%)
|
-2.72M
est: -3.94M (+31.0%)
|
-1.72M
est: -1.75M (+1.4%)
|
-2.39M
est: -1.31M (-82.4%)
|
-4.18M
est: -1.39M (-201.4%)
|
-3.08M
est: -5.99M (+48.6%)
|
-2.07M
est: -1.78M (-16.0%)
|
-891.4K
-891.4K – -891.4K
+50.0% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
6.37M
est: 5.02M (+26.8%)
|
7.32M
est: 5.02M (+45.8%)
|
8.48M
est: 6.68M (+27.0%)
|
8.69M
est: 7.85M (+10.7%)
|
8.23M
est: 8.60M (-4.3%)
|
6.69M
est: 7.97M (-16.0%)
|
5.36M
est: 7.16M (-25.2%)
|
4.32M
est: 5.11M (-15.4%)
|
4.05M
est: 4.64M (-12.6%)
|
5.22M
est: 5.89M (-11.4%)
|
5.87M
est: 4.54M (+29.2%)
|
5.39M
est: 4.94M (+9.1%)
|
3.55M
est: 4.00M (-11.3%)
|
4.92M
4.92M – 4.92M
+23.2% YoY
|
6.03M
6.03M – 6.03M
+22.5% YoY
|
| EPS |
-0.89
est: -0.71 (-25.2%)
|
-1.04
est: -0.81 (-27.8%)
|
-0.82
est: -0.65 (-25.8%)
|
-0.83
est: -0.62 (-34.5%)
|
-0.75
est: -0.22 (-239.3%)
|
-0.37
est: -0.17 (-123.2%)
|
-0.07
est: -0.10 (+28.8%)
|
-0.13
est: -0.08 (-56.8%)
|
-0.06
est: -0.04 (-67.5%)
|
-0.07
est: -0.03 (-169.3%)
|
-0.11
est: -0.07 (-49.3%)
|
-0.06
est: -0.07 (+3.4%)
|
-0.02
est: -0.02 (-16.0%)
|
-0.01
-0.01 – -0.01
+50.0% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pierre Jerome | Co-Founder, Chairman of the Board & Chief Executive Officer | 194.9K | male |
| Stephane Bette | Co-Founder, Deputy Chief Executive Officer & Director | 155.5K | male |
| Anne-Charlotte Millard | Chief Financial Officer | — | female |
| Maurice Bourlion | Co-Inventor & Director | — | male |
| Patricia Lempereur | Vice President of International Sales & Global Marketing | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALSGD.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
